Italy's urgent pro-industry talks face patient wait
This article was originally published in Clinica
Executive Summary
Despite the urgency voiced by Italy’s austerity-beleaguered medtech industry following the elections (www.clinica.co.uk, 28 February 2013), the sector must wait at least another three weeks for parliamentarians to be anywhere near ready to discuss how best to help the country through its economic crisis, including completing the country’s austerity measures. Formalities around the registration of members of the Chamber of Deputies and the Senate will kick off next week, with the first serious talks between the political groups and alliances that emerge due to take place from 15 March, according to a parliamentary calendar described in national reports. These groupings and their leaders are not expected to be in place before 20 March, and the election of the new prime minister is likely to take place in the last week of March. “The range of possible scenarios is wide open and too hard to predict,” according to healthcare news daily Quotidianosanità.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.